The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO)
Abstract
BACKGROUND: atrial fibrillation (AF) is the commonest chronic arrhythmia with a prevalence of 9% in octogenarians and accounts for 24% of the stroke risk in this population. Although trials demonstrate reductions in stroke with warfarin, audit data show that it is still underused. However, anti-coagulation in the very elderly is not without risk. METHODS: randomised open labelled prospective study of primary thromboprophylaxis for AF. Patients aged >80 and <90 were randomised to receive dose-adjusted warfarin (INR 2.0-3.0) or aspirin 300 mg. All patients had permanent AF, were ambulant, had Folstein mini mental score >25 and had no contraindications to either treatment. Follow-up was for 1 year with 3 monthly visits. The primary outcome measure was a comparative frequency of combined endpoints comprising death, thromboembolism, serious bleeding and withdrawal from the study. RESULTS: seventy-five patients (aspirin 39; warfarin 36) were entered (mean age 83.9, 47% male). There were significantly more adverse events with aspirin (13/39; 33%) than warfarin (2/36; 6%), P = 0.002. 10/13 aspirin adverse events were caused by side effects and serious bleeding; there were three deaths (two aspirin, one warfarin). CONCLUSION: dose-adjusted warfarin was significantly better tolerated with fewer adverse events than aspirin 300 mg in this elderly population. Although aspirin 75 mg may have been better tolerated, there is no evidence for efficacy in AF at this dose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atrial fibrillation as an independent risk factor for stroke: the Framingham study
Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991) · Stroke · doi:10.1161/01.str.22.8.983 · Cited by 7,388
Feinberg, W. M. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.155.5.469 · Cited by 2,274
Petersen, P., Godtfredsen, J., Boysen, G., Andersen, E., & Andersen, B. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91200-2 · Cited by 1,820
Stroke Prevention in Atrial Fibrillation Study. Final results.
(1991) · Circulation · doi:10.1161/01.cir.84.2.527 · Cited by 1,696
Canadian atrial fibrillation anticoaguiation (CAFA) study
Connolly, S. J., Laupacis, A., Gent, M., Roberts, R. S., Cairns, J. A., & Joyner, C. (1991) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(91)90585-w · Cited by 1,111
Atrial Fibrillation: A Major Contributor to Stroke in the Elderly: The Framingham Study
Wolf, P. A. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370090041008 · Cited by 1,108
Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301143280227 · Cited by 1,067
STROKEPREVENTIONINATRIALFIBRIL (1994) · The Lancet · doi:10.1016/s0140-6736(94)91577-6 · Cited by 621
The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin
Fihn, S. D., Callahan, C. M., Martin, D. C., McDonell, M. B., Henikoff, J. G., White, R. H., & National Consortium of Anticoagulation Clinics* (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-11-199606010-00004 · Cited by 555
(1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.4.409 · Cited by 369
Samsa, G. P., Matchar, D. B., Goldstein, L. B., Bonito, A. J., Lux, L. J., Witter, D. M., & Bian, J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.7.967 · Cited by 294
Majeed, A., Moser, K., & Carroll, K. (2001) · Heart · doi:10.1136/heart.86.3.284 · Cited by 253
Warfarin Use Among Patients With Atrial Fibrillation
Brass, L. M., Krumholz, H. M., Scinto, J. M., & Radford, M. (1997) · Stroke · doi:10.1161/01.str.28.12.2382 · Cited by 241
National Patterns of Warfarin Use in Atrial Fibrillation
Stafford, R. S. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.22.2537 · Cited by 212
Protheroe, J. (2001) · Western Journal of Medicine · doi:10.1136/ewjm.174.5.311 · Cited by 200
Lip, G. Y. H., Golding, D. J., Nazir, M., Beevers, D. G., Child, D., & Fletcher, R. (1997) · Europe PMC (PubMed Central) · Cited by 182
Screening for atrial fibrillation in primary care
Wheeldon, N. M., Tayler, D. I., Anagnostou, E., Cook, D. J., Wales, C., & Oakley, G. D. (1998) · Heart · doi:10.1136/hrt.79.1.50 · Cited by 104
Is Warfarin Underused in the Treatment of Elderly Persons With Atrial Fibrillation?
Whittle, J. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440250097011 · Cited by 98
Mant, J., Richards, S. H., Hobbs, R. F., Fitzmaurice, D. A., Lip, G. Y. H., Murray, E. T., Banting, M., Fletcher, K., Rahman, J. K., Allan, T. F., et al. (2003) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-3-9 · Cited by 49
Warfarin for non-rheumatic atrial fibrillation: five year experience in a district general hospital
Yousef, Z. R., Tandy, S. C., Tudor, V., Jishi, F., Trent, R. J., Watson, D. K., & Cowell, R. P. W. (2004) · Heart · doi:10.1136/hrt.2003.023325 · Cited by 33
Bleeding during antithrombotic therapy in patients with atrial fibrillation
(1996) · ACC Current Journal Review · doi:10.1016/s1062-1458(97)82156-3 · Cited by 30
Underutilization of antithrombotic therapy in atrial fibrillation
Adhiyaman, V., Kamalakannan, D., Oke, A., et al. (2000) · Journal of the Royal Society of Medicine · doi:10.1177/014107680009300308 · Cited by 28
Review of antithrombotic drug usage in atrial fibrillation
Anğ, Peterson, G. M., Friesen, & Vial (1998) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.1998.00148.x · Cited by 19
The influence of randomized trials on the use of anticoagulants for atrial fibrillation
Mead, G. E. (1999) · Age and Ageing · doi:10.1093/ageing/28.5.441 · Cited by 16
Stroke prevention in elderly patients with atrial fibrillation.
Lew, S., & Lim, J. (2002) · PubMed · Cited by 12
Long‐term management of atrial fibrillation
Camm, A. J., Gallagher, M. M., & Camm, A. J. (1997) · Clinical Cardiology · doi:10.1002/clc.4960200416 · Cited by 5
Warfarin for Stroke Prevention in Octogenarians with Atrial Fibrillation
Howard, P. A., Ellerbeck, E. F., Engelman, K. K., & DUNN, M. I. (2001) · The American Journal of Geriatric Cardiology · doi:10.1111/j.1076-7460.2001.00001.x · Cited by 5
ATRIAL FIBRILLATION IN A GENERAL HOSPITAL: HOW WELL ARE WE DOING?
Bhattacharyya, A., & Sharma, S. (1999) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.1999.tb11724.x · Cited by 2
Mant, J. W. F., Richards, S. H., Hobbs, R., Fitzmaurice, D. A., Lip, G. Y. H., Murray, E. T., Banting, M. V., Fletcher, K., Rahman, J., Allan, T. F., et al. (2003) · University of Birmingham Institutional Research Archive (University of Birmingham) · Cited by 1
Cited by
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Mant, J., Hobbs, F. R., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., & Murray, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61233-1 · Cited by 1,556
Antithrombotic Therapy for Atrial Fibrillation
Lip, G. Y. H., Banerjee, A., Boriani, G., Chiang, C. E., Fargo, R., Freedman, B., Lane, D. A., Ruff, C. T., Turakhia, M., Werring, D., et al. (2018) · Chest · doi:10.1016/j.chest.2018.07.040 · Cited by 939
Wan, Y., Heneghan, C., Perera, R., Roberts, N., Hollowell, J., Glasziou, P., Bankhead, C., & Xu, Y. (2008) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.796185 · Cited by 514
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke
Lansberg, M. G., O'Donnell, M. J., Khatri, P., Lang, E. S., Nguyen-Huynh, M. N., Schwartz, N. E., Sonnenberg, F. A., Schulman, S., Vandvik, P. O., Spencer, F. A., et al. (2012) · Chest · doi:10.1378/chest.11-2302 · Cited by 455
Metadata
- Authors
- Rash, A., Downes, T., Portner, R., Yeo, W. W., Morgan, N., & Channer, K. S.
- Venue
- Age and Ageing
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-01-25
- Volume
- 36
- Issue
- 2
- Pages
- 151-156
- ISSN
- 0002-0729 (ISSN-L)
- 1468-2834
- OpenAlex
- W2150085535
- Cited by
- 285
- References
- 30
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.